Global Anemia Therapeutics Market 2017-2021

  • ID: 4416715
  • Report
  • Region: Global
  • 84 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • AMAG Pharmaceuticals
  • Bayer
  • Daiichi Sankyo
  • Galenica
  • GlaxoSmithKline
  • MORE
About Anemia Therapeutics

It is a medical condition that is characterized by the decrease in RBC count. RBCs make up the blood, and its main function is to deliver oxygen from lungs to other tissues and carbon dioxide from other tissues back to the lungs. This function is accomplished by hemoglobin, an iron-containing biomolecule present at the cytoplasm of an RBC and can efficiently bind to oxygen. In anemia, the decreased RBC count results in the impairment of the body's ability for gas exchange (oxygen and carbon dioxide). This decrease may result from hemolysis (destruction of RBC), hemorrhage (blood loss), or decreased production of RBCs.

The analysts forecast the global anemia therapeutics market to grow at a CAGR of 8.55% during the period 2017-2021 .

Covered in this report
The report covers the present scenario and the growth prospects of the global anemia therapeutics market for 2017-2021 . To calculate the market size, the report considers the sales of branded, generic, and off-label drugs used for the treatment of anemia.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Anemia Therapeutics Market 2017-2021 , has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos
Other prominent vendors
  • Acceleron Pharma
  • Bayer
  • GlycoMimetics
  • GlaxoSmithKline
  • Novartis
  • Pieris Pharmaceuticals
  • Sanofi
Market drivers
  • Presence of large patient pool with various disorders
  • For a full, detailed list, view the full report
Market challenges
  • High cost of drugs
  • For a full, detailed list, view the full report
Market trends
  • Growing focus on emerging economies
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • AMAG Pharmaceuticals
  • Bayer
  • Daiichi Sankyo
  • Galenica
  • GlaxoSmithKline
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
PART 05: Anemia: A brief overview
  • Anemia
  • Symptoms
  • Classification of anemia
  • Causes of anemia
  • Treatment
PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Pipeline Landscape

PART 08: Market segmentation by disease type
  • Iron deficiency anemia
  • Sickle cell anemia
  • Pernicious anemia
  • Hemolytic anemia
  • Others
PART 09: Geographical segmentation
  • Anemia therapeutics market in Americas
  • Anemia therapeutics market in EMEA
  • Anemia therapeutics market in APAC
PART 10: Decision framework

PART 11: Drivers and challenges
  • Market drivers
  • Market challenges
PART 12: Market trends
  • Growing focus on HIF stabilizers
  • Growing focus on emerging economies
  • Increasing strategies of vendors to expand reach of anemia therapeutics
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Complications arising due to anemia
Exhibit 02: Symptoms of anemia
Exhibit 03: Classification of anemia
Exhibit 04: Causes of anemia
Exhibit 05: Treatment approaches for anemia
Exhibit 06: Global anemia therapeutics market
Exhibit 07: Global anemia therapeutics market, 2016-2021 ($ billions)
Exhibit 08: Use of anemia therapeutics
Exhibit 09: Opportunity analysis of global anemia therapeutics market
Exhibit 10: Five forces analysis
Exhibit 11: Pipeline landscape by number of molecules
Exhibit 12: Key clinical trials
Exhibit 13: Global anemia therapeutics market segmentation by disease type
Exhibit 14: Global anemia therapeutics market share by disease type, 2016
Exhibit 15: Global iron deficiency anemia therapeutics market, 2016-2021 ($ billions)
Exhibit 16: Global sickle cell anemia therapeutics market, 2016-2021 ($ billions)
Exhibit 17: Global pernicious anemia therapeutics market, 2016-2021 ($ billions)
Exhibit 18: Types of hemolytic anemia
Exhibit 19: Global hemolytic anemia therapeutics market, 2016-2021 ($ billions)
Exhibit 20: Global anemia therapeutics market by others, 2016-2021 ($ billions)
Exhibit 21: Global anemia therapeutics market share by geography, 2016 and 2021
Exhibit 22: Global anemia therapeutics market by geography, 2016-2021 ($ billions)
Exhibit 23: Market scenario in Americas
Exhibit 24: Anemia therapeutics market in Americas ($ billions)
Exhibit 25: Market scenario in EMEA
Exhibit 26: Anemia therapeutics market in EMEA ($ billions)
Exhibit 27: Market scenario in APAC
Exhibit 28: Anemia therapeutics market in APAC ($ billions)
Exhibit 29: Competitive structure analysis of global anemia therapeutics market 2016
Exhibit 30: AMAG Pharmaceuticals: Key highlights
Exhibit 31: AMAG Pharmaceuticals: Strength assessment
Exhibit 32: AMAG Pharmaceuticals: Strategy assessment
Exhibit 33: AMAG Pharmaceuticals: Opportunity assessment
Exhibit 34: Daiichi Sankyo: Key highlights
Exhibit 35: Daiichi Sankyo: Strength assessment
Exhibit 36: Daiichi Sankyo: Strategy assessment
Exhibit 37: Daiichi Sankyo: Opportunity assessment
Exhibit 38: Galenica: Key highlights
Exhibit 39: Galenica: Strength assessment
Exhibit 40: Galenica: Strategy assessment
Exhibit 41: Galenica: Opportunity assessment
Exhibit 42: Pharmacosmos: Key highlights
Exhibit 43: Pharmacosmos: Strength assessment
Exhibit 44: Pharmacosmos: Strategy assessment
Exhibit 45: Pharmacosmos: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acceleron Pharma
  • AMAG Pharmaceuticals
  • Bayer
  • Daiichi Sankyo
  • Galenica
  • GlaxoSmithKline
  • MORE
New Report Released: – Global Anemia Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global anemia therapeutics market: AMAG Pharmaceuticals, Daiichi Sankyo, Galenica, and Pharmacosmos

Other Prominent Vendors in the market are: Acceleron Pharma, Bayer, GlycoMimetics, GlaxoSmithKline, Novartis, Pieris Pharmaceuticals, and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Growing focus on emerging economies. The growing focus of vendors on emerging economies will create growth opportunities. The emerging countries such as China, India, and Brazil are witnessing an increased prevalence of CKD and other diseases such as congestive heart failure. This has driven vendors to focus on emerging economies, which will enable them to expand their sources of revenue.”

According to the report, one of the major drivers for this market is Presence of large patient pool with various disorders. Intravenous anemia therapeutics have increased in demand owing to the presence of large patient pools globally. Some of the risk factors that lead to anemia include CKD, non-dialysis CKD, congestive heart failure, chemotherapy-induced anemia, inflammatory bowel syndrome, surgeries, heavy uterine bleeding, and postpartum depression. As per the NIH, an estimated 200 million globally, were suffering from CKD in 2014, with low to middle income countries leading the chart. Most of the deaths related to the kidney occur in developing countries largely due to expensive treatment and inappropriate healthcare infrastructure.

Further, the report states that one of the major factors hindering the growth of this market is High cost of drugs. The high cost of drugs associated with the use of anemia therapeutics, particularly the intravenous iron drugs used for the treatment of iron deficiency anemia, may pose a challenge to the market. There are many benefits of intravenous iron drugs over oral iron drugs. However, intravenous iron drugs are costlier than oral iron drugs. This may hinder the adoption rates of intravenous iron drugs and may drive end-users to choose low-cost alternatives.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AMAG Pharmaceuticals
  • Daiichi Sankyo
  • Galenica
  • Pharmacosmos
  • Acceleron Pharma
  • Bayer
  • GlycoMimetics
  • GlaxoSmithKline
  • Novartis
  • Pieris Pharmaceuticals
  • Sanofi
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll